Search for: "BRISTOL-MYERS SQUIBB"
Results 641 - 660
of 863
Sorted by Relevance
|
Sort by Date
30 Apr 2013, 12:14 pm
Bristol-Myers Squibb Company, 2013 U.S. [read post]
6 Feb 2019, 6:12 am
Regulation of medicinal productsGuestKat Frantzeska Papadopoulou explored the issue of the regulation of orphan drugs in the context of the General Court decision on an action brought by Bristol-Myers Squibb Pharma (BMS) against the Commission and the European Medicines Agency (EMA) in the case T‑329/16: Orphan Drugs, a successful regulation after all? [read post]
30 Aug 2019, 5:41 pm
”); Bristol–Myers Squibb Co.v. [read post]
9 Nov 2017, 4:00 am
Earlier this year, the Federal Court of Appeal, in Bristol-Myers Squibb Canada Co. v. [read post]
24 Mar 2015, 11:54 am
Xarelto, has grabbed a 32 percent market share in the highly competitive anticoagulant market, significantly ahead of Boehringer’s Pradaxa and Bristol-Myers Squibb’s Eliquis, the other two new anticoagulants in the market. [read post]
15 Oct 2020, 3:06 am
And don’t forget to tune into our October 29th webcast with CII’s Amy Borrus, Doug Chia of Soundboard Governance, Dorothy Flynn of Broadridge, Independent Inspector of Election Carl Hagberg and Bristol-Myers Squibb’s Kate Kelly to hear what you should be doing right now to prepare. [read post]
31 May 2010, 5:51 am
Bristol-Myers Squibb Co., 2009 U.S. [read post]
3 Apr 2010, 4:02 pm
Where an ad is literally false, the court has the power enjoin the use without reference to the impact of the ad on the buying public (McNeil-PCC v Bristol-Myers Squibb)(1991)). [read post]
3 Feb 2010, 2:00 am
(Docket Report) Sustiva (Efavirenz) – US: Mylan and Matrix fail in bid to dismiss Sustiva case brought by Bristol Myer Squibb (Patent Docs) Temodar (Temozolomide) – US: District Court Delaware: Temador patent unenforceable due to prosecution laches and inequitable conduct: Cancer Research Tech v Barr Labs (Docket Report) (Patent Baristas) (IP Factor) Viread (Tenofovir) – US: Gilead Sciences announces notification of Teva’s ANDA filing for Viread… [read post]
6 Jan 2010, 3:10 am
” In re Bristol-Myers Squibb Co., 975 S.W.2d 601, 603 (Tex. 1998). [read post]
23 Oct 2008, 10:18 am
The Wall Street Journal writes, During his five years as chief executive of Bristol-Myers Squibb ...peterrost.blogspot.com/2006/08/bye-bye-peter-dolan-hello-karen-katen.html - 67k - Cached - Similar pages - Note thisTHE PETER ROST BLOG: Pfizer CEO eliminates Karen Katen executivesJan 23, 2007 ... [read post]
9 Jul 2015, 3:28 pm
Xarelto, has grabbed a 32 percent market share in the highly competitive anticoagulant market, significantly ahead of Boehringer’s Pradaxa and Bristol-Myers Squibb’s Eliquis, the other two new anticoagulants in the market. [read post]
7 Jan 2016, 1:37 pm
From the this December 23, 2015 Reuters news report, "New blood thinner 'antidote' to help doctors move past warfarin", we get some insight about this current "no antidote" situation: Xarelto, from Bayer AG and Johnson & Johnson, and Eliquis, sold by Bristol-Myers Squibb and Pfizer, were approved as safer and more convenient alternatives for preventing blood clots and strokes than warfarin. [read post]
9 Sep 2009, 7:14 am
– Dispute between Wyeth and Dexel (The IP Factor) EpiPen (Epinephrine) – US: King Pharmaceuticals, Meridian Medical Technology file patent infringement suit against Teva following Para IV certification (Patent Docs) Seroxat (Paroxetine) – Israel: not even sublime, just ridiculous – Israel PTO decision in Unipharm v SmithKline Beecham (America-Israel Patent Law) Stelara (Ustekinumab, anti-IL-12 antibody) – Centocor seeks review of BPAI decision… [read post]
19 Mar 2012, 6:20 am
Norman gives a lucid account of Judge Birss QC's summary of principles relevant to the grant or refusal of interim injunctive relief, in a hearty tussle between Bristol-Myers Squibb and Teva over the prospect of the latter launching a generic version of efavirenz. [read post]
31 Oct 2008, 11:53 am
You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com] Highlights this week included: Oxytrol (Oxybutynin) - US: Watson files patent infringement lawsuit against Barr over application to market generic Oxytrol; Barr challenges Oxytrol patent… [read post]
28 Nov 2016, 3:52 am
Abilify’s History Approved by the FDA in 2002, Abilify, which comes in many forms, including a tablet, liquid or an injection (including an extended-release injection), is manufactured by Bristol-Myers Squibb and the Otsuka America Pharmaceutical, and has consistently topped 5 billion dollars in yearly sales. [read post]
28 Jun 2017, 8:34 am
Ability’s manufacturers, Otsuka and Bristol-Myers Squibb, are facing a growing number of lawsuits from patients who claim they couldn’t control the urge to gamble or over-eat, or that they developed hyper sexual behaviors. [read post]
17 Feb 2010, 4:55 pm
Several years later, two of Abbott's competitors (GSK and Bristol-Myers Squibb) introduced two new PIs which were meant to be used in conjunction with booster quantities of Norvir. [read post]
27 May 2020, 3:03 am
Independent chair votes at pharmaceutical companies have received significant support (based on For/For + Against), including: 42% at J&J, where the vote had been increasing in recent years and where there was majority support for another IOPA proposal requesting a board report on governance of opioid-related risks; 34% at Eli Lilly, where it was a first-time proposal and where the vote would be 40% if the Lilly Endowment shares were backed out; 44.5% at Bristol-Myers… [read post]
